These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21948726)

  • 1. FDA panel recommends approval of deferiprone.
    Shuchman M
    CMAJ; 2011 Nov; 183(16):E1159-60. PubMed ID: 21948726
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferiprone approved for iron overload.
    Traynor K
    Am J Health Syst Pharm; 2011 Nov; 68(22):2106. PubMed ID: 22058092
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of oral iron chelator L1.
    Hershko C
    Lancet; 1993 Apr; 341(8852):1088-9. PubMed ID: 8096975
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term therapy with deferiprone.
    Olivieri NF
    Acta Haematol; 1996; 95(1):37-48. PubMed ID: 8604585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of deferiprone in thalassemia.
    Dogherty P; Einarson T; Koren G; Sher G
    Blood; 1997 Jul; 90(2):894. PubMed ID: 9226195
    [No Abstract]   [Full Text] [Related]  

  • 6. Deferiprone for thalassaemia.
    Kontoghiorghes GJ; Agarwal MB; Grady RW; Kolnagou A; Marx JJ
    Lancet; 2000 Jul; 356(9227):428-9. PubMed ID: 10972396
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The controversial role of deferiprone in the treatment of thalassemia.
    Richardson DR
    J Lab Clin Med; 2001 May; 137(5):324-9. PubMed ID: 11329529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally active iron chelators in the treatment of iron overload.
    Olivieri NF
    Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).
    Agarwal MB
    Indian J Pediatr; 1993; 60(4):509-16. PubMed ID: 8262587
    [No Abstract]   [Full Text] [Related]  

  • 11. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):1-5. PubMed ID: 16503822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferiprone or fatal iron toxic effects?
    Kontoghiorghes GJ; Agarwal MB; Tondury P; Marx JJ
    Lancet; 2001 Mar; 357(9259):882-3. PubMed ID: 11265977
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
    Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
    Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferiprone.
    Piga A; Roggero S; Salussolia I; Massano D; Serra M; Longo F
    Ann N Y Acad Sci; 2010 Aug; 1202():75-8. PubMed ID: 20712776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone: new preparation. Poorly assessed.
    Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron chelators for thalassaemia.
    Hershko C; Konijn AM; Link G
    Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A; Felisi M; De Sanctis V; De Mattia D
    Expert Opin Pharmacother; 2003 Oct; 4(10):1763-74. PubMed ID: 14521486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.